West Pharmaceutical Services, Inc.
Every calculator, already run for WST
Open the full toolkit →You have the numbers on WST. Get the argument.
A written report on which of these readings actually decide the outcome for West Pharmaceutical Services, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering WSTAnalyst Price Target Disagreement for West Pharmaceutical Services, Inc.
Wall Street's bull case implies +22% from the current price; the bear case implies -9%. A 32% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for WST
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection a…
WST — frequently asked
Is WST a buy right now?
Wall Street's consensus rating on West Pharmaceutical Services, Inc. is Strong Buy across 17 analysts, with a mean price target of $407.56 (+8% vs. the current $375.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is WST overvalued?
WST trades at 48.0x trailing earnings, against a DCF fair value of $71 per share. The current price implies 29% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is WST's next earnings date?
West Pharmaceutical Services, Inc. is next scheduled to report earnings around Oct 22, 2026. A full WST research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for West Pharmaceutical Services, Inc.?
Analysts covering West Pharmaceutical Services, Inc. (WST) range from a bear-case target of $340.00 to a bull-case high of $459.00, with a mean consensus target of $407.56 across 16 analysts. The spread of $119.00 (32% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare West Pharmaceutical Services, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For West Pharmaceutical Services, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full WST research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on West Pharmaceutical Services, Inc., in minutes. 3 free reports included with every account — no credit card required.